Taiwanese journal of obstetrics & gynecology · 2026
Crizotinib for refractory vulvar malignant melanoma with equivocal MET amplification: a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liang Chia-Jung, Hsiao Sheng-Mou
Аннотация
OBJECTIVE: Report the effect of crizotinib on one woman with refractory vulvar malignant melanoma and equivocal MET amplification.
CASE REPORT: One 62-year-old woman was diagnosed with vulvar malignant melanoma, AJCC stage IV, pT2aN0M1c. She received postoperative adjuvant therapy with 6 cycles of 75 mg/m2 of cisplatin and 200 mg/m2 of temozolomide, and then received pembrolizumab, nivolumab and brachytherapy for recurrence. However, she suffered multiple liver metastases and the recurrence was refractory to repeat pembrolizumab treatment. Next-generation sequencing examination revealed equivocal MET amplification. She received crizotinib (250 mg twice a day) based on the finding of equivocal MET amplification. Partial response was achieved based on the decreased size of liver metastases. However, liver metastasis deteriorated after 6 months of crizotinib. She died later despite salvage radiotherapy.
CONCLUSION: Next-generation sequencing may be suggested for refractory malignant melanoma. Crizotinib may be used to treat malignant melanoma with MET amplification.
CASE REPORT: One 62-year-old woman was diagnosed with vulvar malignant melanoma, AJCC stage IV, pT2aN0M1c. She received postoperative adjuvant therapy with 6 cycles of 75 mg/m2 of cisplatin and 200 mg/m2 of temozolomide, and then received pembrolizumab, nivolumab and brachytherapy for recurrence. However, she suffered multiple liver metastases and the recurrence was refractory to repeat pembrolizumab treatment. Next-generation sequencing examination revealed equivocal MET amplification. She received crizotinib (250 mg twice a day) based on the finding of equivocal MET amplification. Partial response was achieved based on the decreased size of liver metastases. However, liver metastasis deteriorated after 6 months of crizotinib. She died later despite salvage radiotherapy.
CONCLUSION: Next-generation sequencing may be suggested for refractory malignant melanoma. Crizotinib may be used to treat malignant melanoma with MET amplification.